(1-丙基咪唑基-2-基)甲胺 | 886498-05-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1-丙基咪唑基-2-基)甲胺
• 中文别名: 1-(1-丙基-1H-咪唑-2-基)甲胺
• 英文名称: (1-Propyl-1H-imidazol-2-yl)methanamine
• 英文别名: (1-propylimidazol-2-yl)methanamine
• CAS: 886498-05-1
• 化学式: C₇H₁₃N₃
• mdl: MFCD08704460
• 分子量: 139.2
• InChiKey: OMHPFEWBBUELID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  (1-丙基咪唑基-2-基)甲胺 、 2-amino-6-(5-methyl-2-furyl)-pyrimidine-4-carboxylic acid 在 polymer supported carbodiimide 、 1-羟基苯并三唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以30%的产率得到N-(1-n-propyl-imidazol-2-ylmethyl)-2-amino-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide
  参考文献：
  名称：

  Antagonists of the human A2A receptor. Part 6: Further optimization of pyrimidine-4-carboxamides

  摘要：

  Antagonists of the human A(2A) receptor have been reported to have potential therapeutic benefit in the alleviation of the symptoms associated with neurodegenerative movement disorders such as Parkinson's disease. As part of our efforts to discover potent and selective antagonists of this receptor, we herein describe the detailed optimization and structure-activity relationships of a series of pyrimidine-4-carboxamides. These optimized derivatives display desirable physiochemical and pharmacokinetic profiles, which have led to promising oral activity in clinically relevant models of Parkinson's disease. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.07.078

文献信息

• Imidazole‐Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes
  作者：Xuewei Zhao、Jinjin Chen、Min Qiu、Yamin Li、Zachary Glass、Qiaobing Xu

  DOI：10.1002/anie.202008082

  日期：2020.11.2

  Engineering T lymphocytes is an emerging approach in a variety of biomedical applications. However, delivering large biologics to primary T lymphocytes directly in vivo is technically challenging due to the low transfection efficacy. Herein, we investigated a library of synthetic lipid‐like molecules (lipidoids) for their capability of delivering mRNA into primary T lymphocytes both ex vivo and in vivo. We

  工程T淋巴细胞是各种生物医学应用中的新兴方法。然而，由于转染效率低，直接在体内将大量生物制剂直接递送至原代T淋巴细胞在技术上具有挑战性。本文中，我们研究了合成脂质样分子（类脂质）库在体外和体内将mRNA传递至原代T淋巴细胞的能力。最初，我们筛选了一个具有大量结构脂质的离体文库，并鉴定了在T淋巴细胞转染中特别有效的含咪唑的脂质。我们通过构建和筛选包含咪唑或咪唑类似物的详细类脂质库来进行结构-活性相关分析，从而进一步优化类脂质结构。
• LIPID-LIKE NANOCOMPLEXES AND USES THEREOF
  申请人：Trustees of Tufts College

  公开号：US20200368254A1

  公开（公告）日：2020-11-26

  Disclosed are compounds of formula (I) below: wherein each of the variables A, B, X, W, V, R 1 -R 5 , and m are defined herein. Also disclosed are pharmaceutical compositions containing a nanocomplex, wherein the nanocomplex is formed of one of the compounds, and a protein, a nucleic acid, or a small molecule; and methods of treating a medical condition with one of the pharmaceutical compositions.
• Antagonists of the human A2A receptor. Part 6: Further optimization of pyrimidine-4-carboxamides
  作者：Roger J. Gillespie、Samantha J. Bamford、Alex Clay、Suneel Gaur、Tim Haymes、Philip S. Jackson、Allan M. Jordan、Burkhard Klenke、Stefania Leonardi、Jeanette Liu、Howard L. Mansell、Sean Ng、Mona Saadi、Heather Simmonite、Gemma C. Stratton、Richard S. Todd、Douglas S. Williamson、Ian A. Yule

  DOI：10.1016/j.bmc.2009.07.078

  日期：2009.9

  Antagonists of the human A(2A) receptor have been reported to have potential therapeutic benefit in the alleviation of the symptoms associated with neurodegenerative movement disorders such as Parkinson's disease. As part of our efforts to discover potent and selective antagonists of this receptor, we herein describe the detailed optimization and structure-activity relationships of a series of pyrimidine-4-carboxamides. These optimized derivatives display desirable physiochemical and pharmacokinetic profiles, which have led to promising oral activity in clinically relevant models of Parkinson's disease. (C) 2009 Elsevier Ltd. All rights reserved.